{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:38:32Z","timestamp":1788151112720,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.psychres.2020.113470","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T10:23:56Z","timestamp":1600597436000},"page":"113470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients"],"prefix":"10.1016","volume":"293","author":[{"given":"Pan","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2020.113470_bib0001","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/fcp.12424","article-title":"Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia","volume":"33","author":"Alladi","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajp.2016.08.007","article-title":"Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study","volume":"24","author":"Birur","year":"2016","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.psychres.2020.113470_bib0003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychires.2006.10.002","article-title":"Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients","volume":"42","author":"Bozina","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2020.113470_bib0004","first-page":"445","article-title":"MDR1 (ABCB1) polymorphisms: functional effects and clinical implications","volume":"65","author":"Brambila-Tapia","year":"2013","journal-title":"Rev. Invest. Clin."},{"key":"10.1016\/j.psychres.2020.113470_bib0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/070674371405900203","article-title":"Pharmacogenetics of antipsychotics","volume":"59","author":"Brandl","year":"2014","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0006","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2217\/pgs.14.50","article-title":"Pharmacogenetics of second-generation antipsychotics","volume":"15","author":"Brennan","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.psychres.2020.113470_bib0007","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hup.2308","article-title":"Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects","volume":"28","author":"Cabaleiro","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0008","doi-asserted-by":"crossref","first-page":"e2693","DOI":"10.1002\/hup.2693","article-title":"Effects of olanzapine during cognitive and emotional processing in schizophrenia: A review of functional magnetic resonance imaging findings","volume":"34","author":"Del Fabro","year":"2019","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/clpt.2011.70","article-title":"Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility","volume":"90","author":"Dobrinas","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2020.113470_bib0010","first-page":"109","article-title":"5-HT2A receptor promoter polymorphism, -1438 G\/A and negative symptom response to olanzapine in schizophrenia","volume":"37","author":"Ellingrod","year":"2003","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.psychres.2020.113470_bib0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FTD.0000000000000119","article-title":"CYP1A2*1D and *1F Polymorphisms Have a Significant Impact on Olanzapine Serum Concentrations","volume":"37","author":"Fabian","year":"2015","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.psychres.2020.113470_bib0012","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","article-title":"Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans","volume":"63","author":"Ghotbi","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0013","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":"Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure\u2014An impact similar to male gender or smoking in schizophrenic patients","volume":"66","author":"Ghotbi","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0014","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12888-018-1817-5","article-title":"Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia","volume":"18","author":"Hattori","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12888-020-02492-5","article-title":"The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine","volume":"20","author":"Hattori","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/pgs.15.155","article-title":"Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response","volume":"17","author":"Huang","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.psychres.2020.113470_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17425255.2011.532787","article-title":"Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction","volume":"7","author":"Jian-Ping","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.psychres.2020.113470_bib0019","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ajp.2018.10.022","article-title":"An association study of dopaminergic (DRD2) and serotoninergic (5-HT2) gene polymorphism and schizophrenia in a North Indian population","volume":"39","author":"Kaur","year":"2019","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.psychres.2020.113470_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.24869\/psyd.2018.157","article-title":"The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study)","volume":"30","author":"Kurylev","year":"2018","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.psychres.2020.113470_bib0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/tpj.2009.32","article-title":"Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome","volume":"10","author":"Laika","year":"2010","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.psychres.2020.113470_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020070","article-title":"Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia","volume":"8","author":"Li","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.psychres.2020.113470_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2012.10.004","article-title":"An exploratory study on STX6, MOBP, MAPT, and EIF2AK3 and late-onset Alzheimer\u2019s disease","volume":"34","author":"Liu","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.psychres.2020.113470_bib0024","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/JCP.0b013e31824997a8","article-title":"Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid","volume":"32","author":"Mao","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/1872208309666140904113615","article-title":"Pharmacogenomics in psychiatry: implications for practice","volume":"8","author":"Moore","year":"2014","journal-title":"Recent Pat. Biotechnol."},{"key":"10.1016\/j.psychres.2020.113470_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1515\/prilozi-2015-0030","article-title":"Pharmacogenetics and antipsychotic treatment response","volume":"36","author":"Naumovska","year":"2015","journal-title":"Pril."},{"key":"10.1016\/j.psychres.2020.113470_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":"The Relationship Between the Response of Clinical Symptoms and Plasma Olanzapine Concentration, Based on Pharmacogenetics","volume":"30","author":"Nozawa","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2020.113470_bib0028","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000327602","article-title":"Polymorphisms of the 5-HT2A Receptor Gene and Clinical Response to Olanzapine in Paranoid Schizophrenia","volume":"64","author":"Olajossyhilkesberger","year":"2011","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psychres.2020.113470_bib0029","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.biopsych.2004.06.020","article-title":"The -1438A\/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity","volume":"56","author":"Parsons","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0030","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1017\/S146114571300045X","article-title":"DRD2\/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2\/3 receptor binding in healthy controls and patients with major depressive disorder","volume":"16","author":"Savitz","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/JCP.0b013e318204d9e2","article-title":"High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug","volume":"31","author":"Skogh","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0032","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2217\/pgs.13.120","article-title":"Pharmacogenetics of olanzapine metabolism","volume":"14","author":"Soderberg","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.psychres.2020.113470_bib0033","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FPC.0b013e3283602876","article-title":"Influence of CYP1A1\/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure","volume":"23","author":"Soderberg","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.psychres.2020.113470_bib0034","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12888-017-1562-1","article-title":"Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines","volume":"17","author":"Taraskina","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1176\/appi.ajp.163.3.529","article-title":"DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients","volume":"163","author":"Todd","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0036","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euroneuro.2012.01.006","article-title":"Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes","volume":"22","author":"Vehofab","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2020.113470_bib0037","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.ftd.0000246761.82377.a6","article-title":"The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia","volume":"28","author":"Ying-Chi","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2020.113470_bib0038","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2215-0366(18)30049-X","article-title":"Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study","volume":"5","author":"Yu","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2020.113470_bib0039","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2019.00177","article-title":"Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120331310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120331310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:51:18Z","timestamp":1759038678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178120331310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":39,"alternative-id":["S0165178120331310"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113470","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113470"}}